Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

NCT00787267 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

37

Enrollment

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Dasatinib

Sponsor

Duke University

Collaborators

[object Object]